All In Biotech

Drug Trial Radar · NCT05052268

XTX202 in Patients With Advanced Solid Tumors

A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX202 in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

95

Actual

Start

Jan 18, 2022

Primary completion

Mar 22, 2025

Study completion Mar 25, 2025

Sponsor

Lead sponsor
Xilio Development, Inc.Industry
Sponsor type
Industry
First posted
Sep 22, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX202 in Patients with Advanced Solid Tumors

Conditions

  • Advanced Solid Tumor

Interventions

  • XTX202Drug

    XTX202 Monotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Dose Limiting Toxicities (DLTs) (Phase 1 Part 1A Only)Time frame: Cycle 1 day 1 up to just prior to the second dose of study drug at Cycle 2 day 1 (each cycle is 21 days)
  2. Incidence of Treatment-emergent Adverse Events (Phase 1 Only)Time frame: Up to 24 months
  3. Investigator-assessed Objective Response Rate (ORR) Per RECIST 1.1 (Phase 2 Only)Time frame: Up to 24 months
  4. Incidence of Changes in Clinical Laboratory Values (Phase 1 Only) - BiochemistryTime frame: Up to 24 months
  5. Incidence of Changes in Clinical Laboratory Values (Phase 1 Only) - HematologyTime frame: up to 24 months
  6. Incidence of Changes in Clinical Laboratory Values (Phase 1 Only) - Thyroid FunctionTime frame: Up to 24 months
  7. Incidence of Changes in Clinical Laboratory Values (Phase 1 Only) - CoagulationTime frame: Up to 24 months

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • UC San Diego Moores Cancer Center

    La Jolla, California

  • Norris Comprehensive Cancer Center

    Los Angeles, California

  • University of California Los Angeles

    Los Angeles, California

  • Hoag Memorial Hospital Presbyterian- Newport Beach

    Newport Beach, California

  • Georgetown University Medical Center

    Washington D.C., District of Columbia

  • Moffitt Cancer Center

    Tampa, Florida

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa

  • Massachusetts General Hospital

    Boston, Massachusetts

  • HealthPartners Cancer Center at Regions Hospital

    Saint Paul, Minnesota

  • Atlantic Health System/Morristown Medical Center

    Morristown, New Jersey

  • Rutgers Cancer Institute of NJ

    New Brunswick, New Jersey

  • Carolina BioOncology Institute

    Huntersville, North Carolina

  • The Ohio State University Wexner Medical Center James Cancer Hospital and Solove Research Institute

    Columbus, Ohio

  • UPMC Hillman Cancer Center Pavilion

    Pittsburgh, Pennsylvania

  • Sarah Cannon Research Institute

    Nashville, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.